 |
年間契約型資訊服務
商品編碼
1524360
化膿性汗腺炎:KOL的洞察Hidradenitis Suppurativa - KOL Insight |
||||||
價格
簡介目錄
隨著治療方案的顯著進步，化膿性汗腺炎 (HS) 的治療模式正在迅速發展。本報告根據主要 KOL 的見解，對熱射病目前和未來的治療狀況進行了全面分析。特別是艾伯維的Humira（阿達木單抗）作為一線生物療法的關鍵作用、諾華的Cosentyx（蘇金單抗）對阿達木單抗無反應/不能耐受的患者的承諾，以及UCB 的Bimzelx （bimekizumab）。我們還考慮了 HS 治療演算法的進展及其對臨床實踐和藥物開發的影響。
本報告回答的關鍵問題：
- TNF 抑制劑（例如艾伯維的 Humira（阿達木單抗）和強生/默克公司的 Remicade（英夫利西單抗））在目前的 HS 治療中發揮什麼作用？另外，預計會有哪些變化？
- 諾華 Cosentyx（蘇金單抗）等二線治療方案對於對阿達木單抗無反應或不能耐受的患者效果如何？
- UCB 的 Bimzelx (bimekizumab) 在治療 HS 方面的新潛力以及 III 期臨床試驗數據顯示了什麼？
- 治療 HS 的主要生物製劑的療效和安全性如何？
- 隨著新療法的推出，治療範式預計將如何發展？
- 關鍵 KOL（關鍵意見領袖）對 HS 目前和未來的管理策略有何看法？
- 現有的和新的熱射病治療方法的使用預計會發生哪些變化？
- 這些發展對 HS 管理的臨床實務和藥物開發有何策略影響？
本報告的調查對象的領導品牌
|
|
調查對象企業
|
|
目錄
摘要整理
現在·未來的治療流程
調查目的
TNF抑制劑
- 認證核可藥
- Humira (Adalimumab;AbbVie)，Remicade (Infliximab;Johnson & Johnson/Merck & Co.)
IL-17抑制劑
- 認證核可藥
- Cosentyx (Secukinumab;Novartis)
- Bimzelx (bimekizumabu;UCB)
- 開發平台(管線)醫藥品
- izokibeppu (Affibody/ACELYRIN)
- sonerokimabu (MoonLake Immunotherapeutics)
JAK/TYK2抑制劑
- 開發平台(管線)醫藥品
- Povorcitinib (INCB54707;Incyte)
- Rinvoq (Upadacitinib;AbbVie)
- Opzelura (rukisorichinibu;Incyte)
- bureposhichinibu (Priovant Therapeutics)
- Sotyktu (deyukurabashichinibu;Incyte)
其他的作用機制
- 開發平台(管線)醫藥品
- Lutikizumab (ABT-981; AbbVie)
- Spevigo (spesolimab; Boehringer Ingelheim)
- Orismilast (UNION Therapeutics)
- Amlitelimab and SAR442970 (Sanofi)
- Eltrekibart (LY3041658; Lilly)
- MC2-32 (RGRN-305; MC2 Therapeutics)
- Remibrutinib, MAS825, LYS006, iscalimab and ianalumab (Novartis)
- Tavneos (avacopan; Amgen)
- KT-474 (Kymera Therapeutics/Sanofi)
- PTM-001 (Phoenicis Therapeutics)
今後的治療趨勢
- 主要的考察:摘要
附錄
- KOL詳細內容
- 美國的KOL
- 歐洲的KOL
簡介目錄
The treatment landscape for hidradenitis suppurativa (HS) is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for HS, highlighting the pivotal role of AbbVie's Humira (adalimumab) as the primary first-line biologic treatment, the promise of Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab, and the emerging potential of UCB's Bimzelx (bimekizumab). Explore the evolving HS treatment algorithms and the implications for clinical practice and drug development.
Key questions answered:
- What is the current role of TNF inhibitors, such as Abbvie's Humira (adalimumab) and Johnson & Johnson/Merck & Co.'s Remicade (infliximab), in the treatment of HS? What changes are anticipated in their usage?
- How effective are secondary treatment options like Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab?
- What is the emerging potential of UCB's Bimzelx (bimekizumab) in the HS treatment landscape, and what do the Phase III trial data suggest?
- What are the key efficacy and safety profiles of the leading biologic treatments for HS?
- How are treatment paradigms expected to evolve with the introduction of new therapies?
- What insights do leading Key Opinion Leaders (KOLs) provide on the current and future management strategies for HS?
- What are the anticipated changes in the usage of existing and emerging treatments for HS?
- What are the strategic implications of these developments for clinical practice and drug development in HS management?
Key brands covered in this report:
|
|
Companies:
|
|
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
TNF inhibitors
- Approved drugs
- Humira (adalimumab; AbbVie) and Remicade (infliximab; Johnson & Johnson/Merck & Co.)
IL-17 inhibitors
- Approved drugs
- Cosentyx (secukinumab; Novartis)
- Bimzelx (bimekizumab; UCB)
- Pipeline drugs
- Izokibep (Affibody/ACELYRIN)
- Sonelokimab (MoonLake Immunotherapeutics)
JAK/TYK2 inhibitors
- Pipeline drugs
- Povorcitinib (INCB54707; Incyte)
- Rinvoq (upadacitinib; AbbVie)
- Opzelura (ruxolitinib; Incyte)
- Brepocitinib (Priovant Therapeutics)
- Sotyktu (deucravacitinib; Bristol Myers Squibb)
Other mechanisms of action
- Pipeline drugs
- Lutikizumab (ABT-981; AbbVie)
- Spevigo (spesolimab; Boehringer Ingelheim)
- Orismilast (UNION Therapeutics)
- Amlitelimab and SAR442970 (Sanofi)
- Eltrekibart (LY3041658; Lilly)
- MC2-32 (RGRN-305; MC2 Therapeutics)
- Remibrutinib, MAS825, LYS006, iscalimab and ianalumab (Novartis)
- Tavneos (avacopan; Amgen)
- KT-474 (Kymera Therapeutics/Sanofi)
- PTM-001 (Phoenicis Therapeutics)
Future treatment trends
- Key insights summary
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
02-2729-4219
+886-2-2729-4219
全球化膿性汗腺炎市場：按患者、按藥物（povorcitinib、bimekizumab、sonerokimab）、按地區——考慮到 COVID-19 的影響的市場規模和趨勢，以及到 2030 年的預測